The Effect of ICON Treatment on WPL With Patients After Fixed Orthodontic Appliances

Riyadh Colleges of Dentistry and Pharmacy

Status: Unknown

Conditions: White Spot Lesion

Treatments: Drug: CPP-ACPF; Drug: ICON Remineralization

Study type: Interventional

Funder types: Other

Identifiers

NCT03391180

FGR/2018/45

Details and patient eligibility

About

The aim of this study is to determine the effect of ICON on White spot lesions compared to CPP-ACPF plus.

Full description

The participants were categorized to either group (group1) receiving ICON treatment method (Icon, DMG, Germany), or (group 2) who shall be receiving CPP-ACPF treatment method (Tooth Mousse plus).

Enrollment: 120 estimated patients

Sex: All

Ages: 12+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• permanent dentition, in good general health and without systemic diseases, who had received fixed orthodontic treatment.

Exclusion criteria

• Patients with primary dentition, enamel hypoplasia, dental fluorosis or tetracycline pigmentation and carious cavity were excluded.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

120 participants in 2 patient groups

ICON Remineralization

Experimental group

Description:

Firstly, Conditioning of the WSL surface by 15% HCL gel (Icon-Etch, DNG) and subsequent application of the drying solution (Icon-Dry, DMG), Numbers of additional etching intervals have been determined by visual assessment after each of the etch/dry intervals to achieve individual, customized intensities of WSL surface conditioning.

Treatment:

Drug: ICON Remineralization

CPP-ACPF

Active Comparator group

Description:

Participants in group 2 (CPP-ACPF) were treated with applying a pea sized amount of ACC-ACPF plus on a gloved finger of the examiner and rubbed the surface of the labial tooth for 4 minutes with advising the patient to avoid drinking and eating for the next 30 minutes of application.

Treatment:

Drug: CPP-ACPF